EDGAR Filing Documents for 0001129928-14-000008

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001129928-14-000008

Filing Date

2014-03-19

Accepted

2014-03-19 14:03:21

Documents

Period of Report

2013-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	20-F	oncy2013-20f.htm	20-F	1737071
2	AMENDING AGREEMENT BT	ex424amendingagreement-bt.htm	EX-4.24	26717
3	AMENDING AGREEMENT KL	ex425amendingagreement-kl.htm	EX-4.25	26611
4	AMENDING AGREEMENT MC	ex426amendingagreement-mc.htm	EX-4.26	26575
5	SUBSIDIARIES	ex80listofsubsidiaries2013.htm	EX-8.0	4393
6	CEO CERTIFICATION	ex121ceocert.htm	EX-12.1	14709
7	CFO CERTIFICATION	ex122cfocert.htm	EX-12.2	13430
8	CEO CERTIFICATION	ex131ceocert.htm	EX-13.1	7234
9	CFO CERTIFICATION	ex132cfocert.htm	EX-13.2	6144
10	2013 MDA	ex151-2013mda.htm	EX-15.1	424913
11	AUDITOR CONSENT	ex1522013eyconsentletter.htm	EX-15.2	6190
12		ernstyounglogo.jpg	GRAPHIC	6545
13		reovirusa02a01.jpg	GRAPHIC	86821
14		finalonclogo.jpg	GRAPHIC	32654
	Complete submission text file	0001129928-14-000008.txt		2469020

Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7

Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380

ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 000-31062 | Film No.: 14703661
SIC: 2834 Pharmaceutical Preparations